Reports related to this article:
Project(s): View 3 related projects in PECWeb
Plant(s): View 2 related plants in PECWeb
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--With but a scant three months left of 2017, the Pharmaceutical-Biotech Industry is on track for an impressive finish in the U.S. Northeast market region. The region, which comprises Delaware, New Jersey, New York and Pennsylvania, is no rookie when it comes to industry project investment.
Click on the image at right for a view of fourth-quarter Pharmaceutical-Biotech activity in the Northeast.
Despite the relative high cost of living in the Northeast, harsh winters and lucrative incentives now offered in every other part of the U.S., it continues to be an industry magnet for investment. Currently, there are 44 active reported projects found within the Industrial Info Pharmaceutical-Biotech Data Platform, translating to a hefty $1.5 billion in total investment value (TIV). That figure translates to a project average TIV of $34 million.
One of the region's fourth-quarter MVPs--most valuable projects--is Athenex Incorporated's (NASDAQ:ATNX) (Buffalo, New York) massive, $300 million project to construct a grassroot 280,000-square-foot sterile injectables, solid dose and fill/finish plant in Dunkirk, New York. And if that is not enough of a win for the Northeast, following completion of the initial plant, the company has plans to further expand the Dunkirk site, to the tune of $18 million. For more information, view Industrial Info's project reports on the plant construction and expansion.
But, a project does not have to be massive to matter. Take, for example, the $6 million plan to build a warehouse by generic and branded drugmaker Lupin Pharmaceuticals (Somerset, New Jersey) in Somerset. While not requiring expensive process equipment and an extensive list of contractors, it does indicate a commitment to continue manufacturing at its 400 Campus Drive plant, which employs nearly 400 people. And that is win in anybody's playbook. For more information, see Industrial Info's project report.
With three months still left to the year, there remains a chance that a percentage of these projects will be delayed or put on hold. Nothing is ever definite until construction begins. And even then, changes can happen. It is not unheard of to have a project start construction, and then suddenly have everything called to a halt for any number of reasons. Financing, market shift, it's simply the nature of the game.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com.
Click on the image at right for a view of fourth-quarter Pharmaceutical-Biotech activity in the Northeast.Despite the relative high cost of living in the Northeast, harsh winters and lucrative incentives now offered in every other part of the U.S., it continues to be an industry magnet for investment. Currently, there are 44 active reported projects found within the Industrial Info Pharmaceutical-Biotech Data Platform, translating to a hefty $1.5 billion in total investment value (TIV). That figure translates to a project average TIV of $34 million.
One of the region's fourth-quarter MVPs--most valuable projects--is Athenex Incorporated's (NASDAQ:ATNX) (Buffalo, New York) massive, $300 million project to construct a grassroot 280,000-square-foot sterile injectables, solid dose and fill/finish plant in Dunkirk, New York. And if that is not enough of a win for the Northeast, following completion of the initial plant, the company has plans to further expand the Dunkirk site, to the tune of $18 million. For more information, view Industrial Info's project reports on the plant construction and expansion.
But, a project does not have to be massive to matter. Take, for example, the $6 million plan to build a warehouse by generic and branded drugmaker Lupin Pharmaceuticals (Somerset, New Jersey) in Somerset. While not requiring expensive process equipment and an extensive list of contractors, it does indicate a commitment to continue manufacturing at its 400 Campus Drive plant, which employs nearly 400 people. And that is win in anybody's playbook. For more information, see Industrial Info's project report.
With three months still left to the year, there remains a chance that a percentage of these projects will be delayed or put on hold. Nothing is ever definite until construction begins. And even then, changes can happen. It is not unheard of to have a project start construction, and then suddenly have everything called to a halt for any number of reasons. Financing, market shift, it's simply the nature of the game.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com.
